Prion protein NMR structure and familial human spongiform encephalopathies by Riek, R et al.








Prion protein NMR structure and familial human spongiform
encephalopathies
Riek, R ; Wider, G ; Billeter, M ; Hornemann, Simone ; Glockshuber, R ; Wuthrich, K
Abstract: The refined NMR structure of the mouse prion protein domain mPrP(121-231) and the recently
reported NMR structure of the complete 208-residue polypeptide chain of mPrP are used to investigate
the structural basis of inherited human transmissible spongiform encephalopathies. In the cellular form
of mPrP no spatial clustering of mutation sites is observed that would indicate the existence of disease-
specific subdomains. A hydrogen bond between residues 128 and 178 provides a structural basis for
the observed highly specific influence of a polymorphism in position 129 in human PrP on the disease
phenotype that segregates with the mutation Asp-178-Asn. Overall, the NMR structure implies that only
part of the disease-related amino acid replacements lead to reduced stability of the cellular form of PrP,
indicating that subtle structural differences in the mutant proteins may affect intermolecular signaling in
a variety of different ways.
DOI: https://doi.org/10.1073/pnas.95.20.11667





Riek, R; Wider, G; Billeter, M; Hornemann, Simone; Glockshuber, R; Wuthrich, K (1998). Prion protein
NMR structure and familial human spongiform encephalopathies. Proceedings of the National Academy
of Sciences of the United States of America, 95(20):11667-11672.
DOI: https://doi.org/10.1073/pnas.95.20.11667
Proc. Natl. Acad. Sci. USA
Vol. 95, pp. 11667–11672, September 1998
Biophysics
Prion protein NMR structure and familial human
spongiform encephalopathies
ROLAND RIEK, GERHARD WIDER, MARTIN BILLETER*, SIMONE HORNEMANN, RUDI GLOCKSHUBER,
AND KURT WÜTHRICH†
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Contributed by Kurt Wüthrich, July 27, 1998
ABSTRACT The refined NMR structure of the mouse
prion protein domain mPrP(121–231) and the recently re-
ported NMR structure of the complete 208-residue polypep-
tide chain of mPrP are used to investigate the structural basis
of inherited human transmissible spongiform encephalopa-
thies. In the cellular form of mPrP no spatial clustering of
mutation sites is observed that would indicate the existence of
disease-specific subdomains. A hydrogen bond between resi-
dues 128 and 178 provides a structural basis for the observed
highly specific inf luence of a polymorphism in position 129 in
human PrP on the disease phenotype that segregates with the
mutation Asp-178–Asn. Overall, the NMR structure implies
that only part of the disease-related amino acid replacements
lead to reduced stability of the cellular form of PrP, indicating
that subtle structural differences in the mutant proteins may
affect intermolecular signaling in a variety of different ways.
A novel class of infectious pathogens, the prions, have been
proposed to be the cause of transmissible spongiform enceph-
alopathies (TSE) (1, 2). Prions are distinct from bacteria,
viruses, or viroids in that nucleic acids are apparently not
essential for the propagation of the infectious agent (3). TSEs
include kuru, Creutzfeldt-Jakob disease (CJD), fatal familial
insomnia (FFI), and Gerstmann-Sträussler-Scheinker syn-
drome in humans, scrapie in sheep, and bovine spongiform
encephalopathy. They have been reported as sporadic and
inherited as well as infectious disorders. According to the
‘‘protein-only’’ hypothesis (4–6), prion diseases are linked with
the presence of the prion protein (PrP) (7), which is ubiquitous
in mammalian cells in the benign cellular form (PrPC) and is
in rare instances transformed into the disease-related scrapie
form (PrPSc).
The infectious, disease-related form of the PrP, PrPSc, has so
far only been observed as an insoluble oligomer that displays
partial resistance to proteinase K digestion and has character-
istics of an amyloid (1, 2, 8). Based on Fourier transform
reflection infrared spectroscopy it was concluded that a sig-
nificant percentage of the polypeptide chain in PrPSc forms
b-sheet secondary structure (9, 10). Attempts to identify
posttranslational modifications of the covalent structure that
would be related to the rare conversion of the ubiquitous PrPC
into PrPSc have been unsuccessful. Although this finding
indicates that prion diseases might indeed be disorders of
protein conformation, no one has succeeded as yet to generate
infectious PrPSc in vitro, either from previously denatured
infectious material, natural PrPC, or from recombinant or
synthetic PrP or fragments thereof (see also ref. 11).
The cellular form of mammalian PrP, PrPC, consists of a
single polypeptide chain that contains two glycosylation sites
and is attached to the cell surface by a glycosyl-phosphatidyl-
inositol anchor at its carboxyl terminus (12). After separation
from the cell membrane, mammalian PrPC is a water-soluble,
protease K-sensitive protein. The NMR structures of intact
recombinant mouse PrPC, mPrP(23–231) (13), and its C-
terminal domain, mPrP(121–231) (14), have been determined,
and this paper presents a refinement of the mPrP(121–231)
structure.
Correlations between the molecular structure of prion pro-
teins and their role in the pathology of TSEs previously have
been discussed on the basis of structure predictions (15–17).
The NMR structure of mPrPC (Figs. 1 and 2, refs. 13 and 14)
now provides a basis for such work. The mouse and human
prion proteins have identical global folds for the domain of
residues 121–231 (R. Zahn, R.R., G.W., and K.W., unpub-
lished work), as expected from the 93% sequence identity (18).
All eight sequence positions in this domain for which amino
acid substitutions have been related to human genetic TSEs (1)
contain identical amino acids in the wild-type mouse and
human proteins (18), and all amino acids that are in direct
contact with these residues in the refined three-dimensional
structure of mPrPC are also identical in the two species. On this
basis we use the NMR structure of mPrPC to investigate likely
structural and functional consequences of the disease-related
amino acid substitutions in human PrP (hPrP) and to critically
evaluate a previously advanced general concept that inherited
TSEs might be related to destabilization of the three-
dimensional structure of PrPC (15–17).
MATERIALS AND METHODS
Isotope-labeled mPrP(121–231) was prepared as described
previously (14, 19). NMR measurements were performed on
Bruker AMX500 and AMX600 and Varian Unity1750 spec-
trometers. For data processing and spectral analysis we used
the programs PROSA (20) and XEASY (21), respectively. Ster-
eospecific assignments for the methyl groups of Val and Leu
were obtained with 10% biosynthetically directed 13C-labeling
of the protein (22).
The input of nuclear Overhauser effect (NOE) distance
constraints for the structure calculation was obtained from the
following 750-MHz data sets: three-dimensional 13C-resolved
[1H,1H]-NOE spectra (23) with tm 5 50 ms, using 13Cy15N-
labeled protein; three-dimensional 15N-resolved [1H,1H]-NOE
spectra (24) with tm 5 50 ms, using 15N-labeled protein; and
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two-dimensional [1H,1H]-NOE spectra (25) in H2O and 2H2O
solution with tm 5 50 ms, using unlabeled protein. The NOE
intensities were calibrated with the tools of the program
DYANA (26). Other tools of DYANA were used to eliminate
NOEs that represent no true conformational constraints and,
where required, pseudo-atoms were introduced with appro-
priate corrections (27). Supplementary constraints were: From
Ca chemical shifts deviating from the random coil values,
2120° , f , 220° and 2100° , c , 0° for Dd(Ca) . 1.5 ppm;
2200° , f , 280° and 40° , c , 220° for Dd(Ca) , 21.5 ppm
(28). With these constraints and intraresidual and sequential
NOEs, HABAS (29) yielded 229 constraints on dihedral angles
f, c, and x1. The usual limits were used for the disulfide bond
Cys-179—Cys-214 (30).
When using ASNO (31) a final input for the structure
calculation of 1,592 NOE upper-limit distance constraints, 229
dihedral angle constraints and the six disulfide bond con-
straints (30) were obtained. The calculation was started with 50
randomized conformers, and the 20 best DYANA conformers
were energy-minimized in a water bath using the AMBER force
field (32) in the program OPAL (33). The mean structure of
mPrP(121–231) used for the illustrations was obtained by
averaging the coordinates of the 20 refined conformers after
superposition of the backbone atoms of residues 124–166 and
172–226 and subsequent energy minimization.
RESULTS AND DISCUSSION
The NMR structure of the soluble form of the mouse PrP
mPrP(23–231) consists of a globular C-terminal domain of
residues 126–226 (Fig. 1a), a flexible unstructured 103-residue
N-terminal tail, and a flexibly disordered C-terminal segment
FIG. 1. Global features of the refined NMR structure of mPrP(121–231). (a) Backbone of residues 126–226 of the mean structure of mPrP(121–231)
as a spline function through the Ca positions. The variable radius of the yellow cylinder is proportional to the mean global backbone displacement per
residue evaluated after superposition of the 20 conformers used to represent the solution structure for best fit of the atoms N, Ca, and C9 of residues
126–166 and 172–226. The chain ends and some sequence locations are indicated. (b) Backbone 126–226 represented with helices as red ribbons, the
b-sheet as yellow ribbons, and the loop regions as orange tubes. The disulfide bond Cys-179–Cys-214 is indicated in green. The hydrophobic core containing
residues 134, 137, 139, 141, 158, 161, 175, 176, 179, 180, 184, 198, 203, 205, 206, 209, 210, and 213–215 (see text) is shown in a translucent envelope. Outside
of the core all hydrogen bonds involving side chains (blue stick models) are represented by dashed cyan cylinders and labeled by a code of lowercase letters
that refers to Table 2. (c) Superposition for best fit of the backbone atoms of residues 126–219 of the refined structure in b with the structure from ref.
14, which is drawn in gray. The three helices are identified as a1, a2, and a3. (d) Location of mutations that in the homologous hPrP have been associated
with inherited prion diseases (see text). Helices 2 (on the right) and 3 are drawn as gray cylinders, the connecting loop as a gray tube, and the two-stranded
b-sheet as a yellow plane. The disulfide bond is identified by green coloring. The mutation sites that segregate with CJD are colored blue, the
Gerstmann-Sträussler-Scheinker syndrome mutation sites are cyan, and the site of the polymorphism MyV129 is red. The amino acids in the mouse sequence,
which are shown here, are in all cases identical to those in the human protein. This figure and Fig. 2 were prepared with the program MOLMOL (45).
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227–231 (13, 34). Suitably isotope-labeled mPrP(121–231)
preparations were used to collect NMR data for a structure
refinement of the globular domain. Although the initial struc-
ture determination (14) described the global fold and the
spatial distribution of the amino acid side chains, the refined
structure further affords a detailed description of the side-
chain packing (Figs. 1b and 2).
The Refined NMR Structure of mPrP(121–231). Table 1
gives a survey of the solution conditions used, the input of
conformational constraints, and the quality of the structure
determination. Key data are that the structurally defined
polypeptide segments include residues 124–166 and 172–226,
as compared with 125–166 and 177–219 in the previous work
(14), and that the rms deviation values for the backbone and
all heavy atoms of these residues are 0.8 Å and 1.2 Å,
respectively, as compared with 1.4 Å and 2.0 Å in ref. 14. The
thickness of the yellow cylindrical rod in Fig. 1a represents the
variable precision of the backbone structure determination
along the sequence from residues 124–226.
The global polypeptide fold of mPrP(121–231) contains
three a-helices with residues 144–154, 175–193, and 200–219,
two b-strands with residues 128–131 and 161–164, and a short
segment of helix-like structure with residues 222–226 (Fig. 1a).
Comparison with the initial NMR structure (14) (Fig. 1c)
shows that helices 2 and 3 have been extended by four residues
at the N terminal end and by two residues at the C-terminal
end, respectively (Fig. 1c) (35), which is a consequence of the
improved definition of these segments (36), and the residues
220–226 are somewhat better defined (see below). During the
refinement the axis of helix 3 has been slightly shifted relative
to the other regular secondary structures.
Although the local precision of the structure determination
generally was improved during the refinement, some short
peptide segments remain poorly defined. In addition to the
flexibly disordered chain-terminal segments 121–125 and 227–
231 (14), these segments include residues 167–171 in the loop
connecting the second b-strand with helix 2 and the last two
turns of helix 2 with the sequence –Thr188–Val–Thr–Thr–Thr–
Thr193–. With regard to the pathology-related conformational
polymorphism in position 129 of hPrP (37), the b-sheet in PrPC
attracts particular interest. Although residues 129, 131, 161,
163, and 164 show typical b-sheet deviations of the 13Ca
chemical shifts from the random coil values (38), the Ha
chemical shifts and the 3JHNa coupling constants in the first
FIG. 2. Close-ups of individual mutation sites: (a) D178N and T183A, (b) Q217R, (c) F198S, and (d) V180I and V210I. Color code: white,
polypeptide backbone; orange, side chains for which a mutation has been associated with inherited human prion diseases; yellow, side chain
carbon—carbon bonds; blue, bonds to side-chain nitrogen atoms and selected backbone amide groups; red, bonds to side-chain oxygen atoms and
selected backbone carbonyl oxygens. The hydrogen bonds are represented by broken cyan cylinders. (a) An empty cavity observed in wild-type
mPrP(121–231) is shown as a gray surface. (b) All bonds within a slice of approximately 18 Å thickness and (c) those within an 10 Å slice. (c) The
orange transparent surface represents the empty space that would be left after the amino acid replacement F198S in the absence of any subsequent
structural rearrangement. (d) All side chains of helices 2 and 3 are shown for which the inter-helix distance between at least one pair of side-chain
heavy atoms is shorter than 5 Å.
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b-strand are close to the random coil values, which may
indicate local conformational averaging. On the other hand,
there is a hydrogen bond from the amide proton of Met-134 to
the carbonyl oxygen of Asn-159 that would be compatible with
an elongation of the b-sheet toward the first helix, with a
b-bulge at residue 132, which is again indicative of dynamic
plasticity of the b-sheet.
The mPrP(121–231) preparations used in the initial study
(14) showed proteolytic cleavage at Tyr-226–Asp-227, which
gave rise to multiple NMR lines for the C-terminal region so
that the structure could not be characterized beyond residue
219. The presently used more stable protein preparations
enabled a structural characterization to residue 226. Helix 3 is
well characterized up to Thr-219, but residues 220 and 221 gave
broad peaks and only a small number of NOEs could be
observed, indicating structural disorder and possibly increased
mobility. For residues 222–225 typical a-helix NOE distance
constraints (36) were observed in mPrP(23–231) (13) as well
as in mPrP(121–231). The structure calculation using the
ensemble of all conformational constraints yielded the struc-
ture shown in Fig. 1, with helix 3 linked to a distorted helical
turn by a nonregular dipeptide. However, because all long-
range constraints of the segment 222–226 are with residues in
or adjacent to the disordered loop of residues 167–171, the
three-dimensional arrangement of segment 220–226 remains
uncertain.
NMR structures also have been presented of the polypeptide
fragments of residues 90–231 and 29–231 of the PrP from
Syrian hamster, shPrP(90–231) (ref. 39; PDB ID code 2PRP)
and shPrP(29–231) (40). The polypeptide backbone fold in
shPrP coincides with that of Fig. 1a, except that the loop of
residues 167–171 is reported to be well defined based on
complete resonance assignments, that helix 3 is described as a
straight helix extending from residues 200–227, and that the
polypeptide segment 132–144 between the first b-strand and
helix 1 shows locally somewhat different arrangements in the
two proteins.
The major result of the present structure refinement for
mPrP(121–231) is the precise structural definition of a large
fraction of the amino acid side chains. Twenty residues form
a tightly packed hydrophobic core. In Fig. 1b the outer confines
of the core are indicated by a translucent sheet. Thirteen
residues in the hydrophobic core come from the antiparallel
helices 2 and 3, which have mutual interactions through the
residues Phe-175, Val-176, Val-180, Ile-184, Val-203, Met-206,
Val-210, and Met-215, and the disulfide bridge Cys-179–Cys-
214, whereas Met-205, Val-209, and Met-213 interact with the
four core residues Met-134, Pro-137, Ile-139, and Phe-141 in
the loop between the first b-strand and the first helix (Fig. 1b).
Pro-158 and Val-161 are adjacent and within the b-sheet,
respectively, and Phe-198 is located in the loop between helices
2 and 3.
The hydrophobic core is surrounded by an outer shell of
protein structure that contains 22 hydrogen bonds with amino
acid side chains (Fig. 1b and Table 2), which include medium-
range interactions in all three helices and a variety of longer-
range interactions. The N terminus of the first helix contains
the hydrogen bond Asn-143Hd– O«Glu-146 (b in Fig. 1b),
which is directly supported by NOEs between dNH2 of Asn-143
and gCH2 of Glu-146. A hydrogen bond between the backbone
oxygen of Asn-171 and the side chain of Asn-174 (l in Fig. 1b)
initiates the second helix. The side chain of Thr-183, which also
acts as an acceptor for a long-range hydrogen bond with the
amide proton of Tyr-162, forms a hydrogen bond to the
carbonyl oxygen of Cys-179, as is supported by the fact that of
the hydroxyl proton of Thr-183 exchanges sufficiently slowly to
be observed by 1H NMR. The N terminus of the third helix is
stabilized by a capping box (41) of Thr-199HN–OdAsp-202 and
Asp-202HN–OgThr-199, and the side chain–side chain hydro-
gen bond Thr-199OHg–OdAsp-202 (r, s, and t in Fig. 1b).
Among the longer-range hydrogen bonds connecting different
groups within the outer shell there are the two hydrogen bonds
Tyr-128Hh–OdAsp-178 and Tyr-162HN–OgThr-183 (a and j in
Fig. 2b), and the salt bridge Arg-164–Asp-178 (k in Fig. 1b),
which hold the b-sheet against helix 2. The salt bridge Arg-
Table 1. Characterization of the energy-minimized NMR structure of mPrP(121–231)
Quantity 20 conformers Mean structure*
Number $0.1 Å 2.8 6 1.6 0
Maximum (Å) 0.10 6 0.0 0.08
Residual dihedral angle constraint violations
Number $1.5 deg. 1.7 6 1.0 0
Maximum, deg. 1.9 6 0.3 1.3
AMBER energies, kcalymol
Total 25,061 6 67 24,777
Van der Waals 2330 6 19 2348
Electrostatic 25,679 6 73 25,303
rms deviation from ideal geometry
Bond lengths, Å 0.0078 6 0.002 0.0074
Bond angles, deg. 2.33 6 0.05 1.62
Peptide bonds, deg. 9.7 6 2.3 10.7
rms deviation to the averaged coordinates, Å
N, Ca, C9 (124–166, 172–226) 0.8 6 0.1
Same plus best defined side chains† 0.8 6 0.1
mPrP(121–231) was studied in aqueous solution containing 0.8 mM protein, pH 5 4.5, T 5 20°C. The
structure determination was based on sequence-specific assignments for 98% of all 1H, 13C, and 15N nuclei.
The missing 1H assignments include all resonances of Asp-167, the backbone resonances of Gln-168, 1HN
of Tyr-169, Ser-170, and Asn-171, the nonaromatic resonances of Phe-175, and the side-chain resonances
of Glu-220. The input for the final structure calculation consisted of 1,592 NOE upper distance limits (388
intraresidual, 428 sequential, 413 medium range, 363 long range) and 229 dihedral angle constraints. The
average residual target function value for the 20 best DYANA conformers was 1.02 6 0.48 Å2.
*The energy-minimized mean structure differs from the average of the atom coordinates of the 20
conformers by a rms deviation of 0.5 Å calculated for the backbone atoms of residues 124–166 and
172–226.
†Best-defined side chains are those with a displacement of the heavy atoms smaller than 1.0 Å and include
residues 130, 132–134, 137, 139, 141, 146, 149, 153, 158–161, 178–184, 188–192, 199, 201–203, 205–207,
209, 210, and 213–216.
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156–Glu-196 (g in Fig. 1b) orients the C-terminal end of helix
1 toward the loop connecting the other two helices.
Most of the residues located in the hydrophobic core as well
as those involved in outer shell hydrogen bonds of mPrP(121–
231) are strictly conserved among mammalian species (18, 35).
Exceptions are position 139, which contains Ile in all but three
mammalian species and Met in Syrian hamster, and seems to
be a key residue in the species barrier between mouse and
hamster (42); Ile-184 and Val-203, which are exchanged in a
correlated manner so that the local packing requirements are
preserved (35); and Met-205 and Val-215. The only noncon-
served hydrogen bond-forming side chains listed in Table 2 are
Asn-143, Arg-164, and Asn-174; all three, however, are ex-
changed conservatively so that corresponding hydrogen bonds
may be maintained in the prion proteins from all different
species.
Local Structures Near Mutation Sites that Segregate with
Inherited Human TSEs. According to a previously advanced
hypothesis the amino acid replacements in hPrP that segregate
with inherited human TSEs should result in reduced stability
of the three-dimensional structure of the PrPC form and thus
enhance the tendency of PrPC to undergo transitions to other
conformational states, including states that may lead to PrPSc
formation (15–17). In hPrP the polypeptide segment 121–231
contains eight of 11 amino acid replacements that have been
associated with familial TSEs (1, 43), which all are located
within or sequentially adjacent to helices 2 and 3 (Fig. 1d).
The most interesting observations relate to the amino acid
replacement Asp-178–Asn (Fig. 2a), which removes the salt
bridge between the strictly conserved residues Asp-178–Arg-
164 (18, 35) (k in Fig. 1b). We thus predict that this variant
protein has reduced thermodynamic stability when compared
with wild-type mPrP(121–231). The phenotype of the prion
disease that segregates with the mutation in position 178 has
been shown to be determined by the nature of the amino acid
residue in position 129, i.e., Met-129yAsn-178 correlates with
fatal familial insomnia and Val-129yAsn-178 with CJD (44).
Two hydrogen bonds in wild-type mPrP(121–231) (Fig. 2a) link
the side chain of Asp-178 with two side chains in the b-sheet,
one of which is sequentially adjacent to position 129. Thus, the
Asp-178–Asn exchange may affect the hydrogen bonding
network involving Arg-164, Tyr-128, and Asp-178 somewhat
differently depending on the nature of the amino acid residue
in position 129. The observed specific interactions between
positions 129 and 178 (Fig. 2a) then would also provide a
rationale for the observation that the ValyMet-129 polymor-
phism does not affect the phenotypes of the inherited TSEs
that segregate with the other known mutations (Fig. 1d).
The mutation Thr-183–Ala (Fig. 2a) eliminates two hydro-
gen bonds that establish a link between helix 2 and the b-sheet,
i.e., Thr-183OHg–O9Cys-179 and Tyr-162HN–OgThr-183 (j
and m in Fig. 1b), indicating reduced stability for this protein
variant.
For the amino acid replacement Gln-217–Arg (Fig. 2b) the
NMR structure indicates reduced stability of PrPC: in the
wild-type protein, Gln-217 is surrounded by hydrophobic
groups (Fig. 2b), and its side chain forms a long-range hydro-
gen bond to the carbonyl oxygen of Ala-133, thus stabilizing a
distinct position of the loop between the first b-strand and
helix 1 relative to the hydrophobic core. The replacement
Gln-217–Arg introduces a positive charge into this otherwise
uncharged region (the nearest charged group is about 10 Å
away), and it appears most unlikely, for steric reasons, that a
satisfactory hydrogen bond geometry with the carbonyl oxygen
of Ala-133 could be achieved with the Arg side chain.
The replacement of Phe-198 in the hydrophobic core by Ser
is a pronouncedly nonconservative mutation. In the absence of
follow-up structural changes this mutation would lead to an
empty cavity that could accommodate 2–3 water molecules
(Fig. 2c). In the wild-type protein the aromatic ring is sur-
rounded by numerous hydrogen-bonded polar side chains (g,
r, s, and t in Fig. 1b) and its replacement by serine is likely to
result in a modified pattern of polar interactions. These
interactions could trigger a collapse of the cavity, which, in
turn, would influence the surface structure and thus could also
alter the ligand binding properties of PrPC. In view of the
anticipated complex structural rearrangement, it is difficult to
estimate the concomitant change in thermodynamic stability,
but significantly reduced stability would be anticipated.
Finally, there are four amino acid replacements for which
the NMR structure predicts no or at most minor variations in
stability. The mutations Glu-200–Lys and Arg-208–His (Fig.
1d) are located on the protein surface, so that even the change
in overall charge of the protein should not have a major impact
on the global structure. For the replacement of Val by Ile in
either positions 180 or 210 (Fig. 2d) there is enough space to
accommodate the somewhat larger Ile side chain.
CONCLUSIONS
The refined NMR structure of mPrP(121–231) and the recent
determination of the solution structure of the intact mPrP,
mPrP(23–231) (13) show convincingly, in contrast to earlier
suggestions (15, 16), that familial human TSEs generally
cannot be rationalized by the assumption of reduced stability
of the PrPC form of the mutant proteins. First, three point
mutations that segregate with inherited TSEs are in the
flexibly extended polypeptide segment N terminal to residue
121 (13), where it is unlikely that individual amino acid
substitutions would measurably affect the global stability of
PrPC. Second, for the eight protein species with disease-related
amino acid exchanges in the globular C-terminal domain the
refined NMR structure of wild-type mPrP(121–231) predicts
largely different effects on the protein stability, from very
small variations relative to the parent protein to major desta-
Table 2. Hydrogen bonds with amino acid side chains in the NMR
structure of mPrP(121–231)
Donor Acceptor n*
a Tyr-128Hh OdAsp-178 11
b Asn-143Hd O«Glu-146 16
c Tyr-149Hh OdAsp-202 16
d Tyr-150Hh O9Pro-137 17
e Arg-151Hh O«Glu-152 8
f Asn-153Hd O9Tyr-149 18
g Arg-156Hh O«Glu-196 13
h Tyr-157Hh O9Asp-202 7
i Gln-160H« O9Gly-131 19
j Tyr-162HN OgThr-183 12
k Arg-164Hh OdAsp-178 7
l Asn-174Hd O9Asn-171 12
m† Thr-183OHg O9Cys-179 6
n Thr-188OHg O9Ile-184 12
o Thr-191OHg O9His-187 8
p Thr-192OHg O9Glu-196 7
q Lys-194Hz O«Glu-196 7
r Thr-199HN OdAsp-202 17
s Thr-199OHg OdAsp-202 14
t Asp-202HN OgThr-199 15
u Thr-216OHg O9Gln-212 10
v Gln-217H« O9Ala-133 8
All hydrogen bonds are listed that occur in more than 35% of the
20 energy-refined conformers used to represent the solution structure.
The notations a through v relate to the visualization of the hydrogen
bonds in Fig. 1b.
*n is the number of conformers, out of the group of 20 conformers used
to represent the NMR structure, that contain the hydrogen bond.
†This hydrogen bond is listed although not all criteria for H-bond
identification were satisfied.
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bilization caused by loss of internal hydrogen bonds and salt
bridges. These structure-based predictions on the relative
thermodynamic stabilities of the individual variant proteins
coincide qualitatively with experimental measurements using
the corresponding recombinant protein variants of mPrP(121–
231) (R. Glockshuber, personal communication). The refined
NMR structure of mPrP(121–231) further shows that the
mutation sites related to the human TSE phenotypes Gerst-
mann-Sträussler-Scheinker syndrome (GSS) and CJD do not
form separate clusters in the three-dimensional structure of
PrPC (Fig. 1d), excluding the presence of GSS- and CJD-
specific subdomains, and it presents a rationale for the specific
influence of the residue type in the polymorphism site 129 on
the TSE phenotypes that segregate with the mutation Asp-
178–Asn (44).
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